Parexel named “Best Contract Research Organization” at 17th Annual ViE Awards
Durham: Parexel, a clinical research
organizations (CROs) providing the full range of Phase I to IV clinical development services, has announced it has been named “Best Contract Research Organization” at the 17th Annual Vaccine
Industry Excellence (ViE) Awards.
Winners were named across 13 categories, including Best Contract
Research Organization, which recognizes the role of CROs in supporting the development of safe and
effective vaccines.
“We are honored to be recognized with this year’s ViE Award for Best Contract Research Organization,”
said Amy McKee, MD, Chief Medical Officer & Head of Oncology Center of Excellence. “This
accomplishment reflects the depth of experience and commitment of our cross-functional infectious
disease and vaccine experts and global delivery team to develop leading preventive and therapeutic
vaccines that advance global health. We look forward to our continued collaboration with our
biopharmaceutical customers in this important area to improve patient outcomes.”
Parexel was named from among eight CRO finalists.
A distinguished industry advisory board selected the
company based on its ability to: provide a range of services in niche and core therapeutic areas;
demonstrate methods of performance improvement and introduction of new services; ensure attention to
and quality of relationships with clients; reach milestones and final outcomes; and build and maintain
existing and long-term partnerships.
Over the last five years Parexel has conducted more than 225 clinical projects in the infectious disease
and vaccine therapeutic area involving more than 9,150 global sites. Parexel’s Infectious Disease and
Franchise core team is led by Anne Kasmar, MD, MSc, Senior Vice President and Global Therapeutic
Head of Infectious Disease and Vaccines.
The annual ViE Awards, organized by Terrapin, showcase excellence in the global vaccine industry. Parexel was recognized at the ViE Awards
ceremony during the World Vaccine Congress on April 2 in Washington, D.C.
Read also: Peyton Howell to become next CEO of Parexel
